Baldessarini R J (1996) Drugs and the treatment of psychiatric disorders. In Hardman J G, Limbird L E, Molino¡ P B, Ruddon R W, Gilman AG (eds), Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn.McGraw-Hill, New York, pp. 399–459
2.
Baldessarini R J, Tondo L (1998) E¡ects of lithium treatment in bipolar disorders and post-treatment-discontinuation recurrence risk. Clin Drug Invest15: 337–351
3.
Baldessarini R J, Suppes T, Tondo L (1996) Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Therapeut3: 492–496
Hyman S E, Nestler E J (1996) Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry153: 151–162
6.
Rosenbaum J, Fava M, Hoog S L, Ascroft R C, Krebs W B (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry44: 77–87
7.
Tondo L, Baldessarini R J, Floris G, Silvetti F, Hennen, J, Tohen M, Rudas N (1998) Lithium treatment reduces risk of suicidal behavior in bipolar disorder patients. JClin Psychiatry59: 405–414
8.
Viguera AC, Baldessarini R J, Hegarty J M,Van Kammen D, Tohen M (1997) Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry54: 49–55
9.
Viguera AC, Baldessarini R J, Friedberg J (1998) Risks of interrupting continuation or maintenance treatment with antidepressants in major depressive disorders. Harvard Rev Psychiatry5: 293–306
